Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy.


BACKGROUND Immunotherapies targeting cellular immunity are currently approved for treatment of melanoma, renal cell carcinoma, and prostate cancer. Studies on the immunogenicity and immune responsiveness of pediatric tumors are limited, therefore, it remains unclear to what extent T-cell-based immunotherapy holds promise for pediatric solid tumors… (More)
DOI: 10.1002/pbc.23048


4 Figures and Tables

Slides referencing similar topics